Trials: EGFR Mutation Status in aNSCLC Patients

N/A N=314 T790M Mutation on ctDNA in Patients With NSCLC After EGFR-TKI Failure

Non-small Cell Lung Cancer Stage III · Non-Small-Cell Lung Cancer Metastatic

Primary: Number of Patients With T790M Mutation Detected by Amplification Refractory Mutation System (ARMS) Assay — 97 participants

First People's Hospital of Hangzhou Results Aug 2016 0.0% serious AE View details

Phase 2 N=100 Erlotinib in Patients With Resected, Early Stage NSCLC With Confirmed Mutations in the EGFR

Non-small Cell Lung Cancer

Primary: 2-year Disease-free Survival — 88 Participants

Massachusetts General Hospital Results Dec 2018 20.0% serious AE View details

N/A N=462 The Study Observes How Long Patients With Non-small Cell Lung Cancer (NSCLC) Benefit From Treatment With Epidermal Growth Factor Tyrosine Kinase Inhibitor (EGFR-TKI) When Given Either for Uncommon Mutations or for Common Mutations in the Sequence Afatinib Followed by Osimertinib

Non-squamous, Non-Small Cell Lung Cancer

Primary: Time on Treatment With Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor (EGFR-TKI) — 9.89; 27.7 Months

Boehringer Ingelheim Results May 2023 22.8% serious AE View details

N/A N=3,382 Asia Pacific and Russia Diagnostic Study for EGFR Testing

EGFR Mutation Status in aNSCLC Patients

Primary: Overall Tumour Epidermal Growth Factor Receptor (EGFR) Mutation Status — 59.2; 52.0; 77.4; 70.7 Percentage of participants

AstraZeneca Results Mar 2016 View details

Phase 2 N=41 Single-arm Trial of BIBW 2992 (Afatinib) in Demographically and Genotypically Selected NSCLC Patients

Carcinoma, Non-Small-Cell Lung

Primary: Percentage of Participants With Best Objective Response — 2 Percentage of participants

Boehringer Ingelheim Results Oct 2013 46.3% serious AE View details

Phase 2 N=154 A Molecular Profiling Study of Patients With EGFR Mutation-positive Locally Advanced or Metastatic NSCLC Treated With Osimertinib

EGFR Mutation Positive Locally Advanced or Metastatic Non-Small Cell Lung Cancer

Primary: Proportion of Patients With a Given Tumour Genetic and Proteomic Marker at the Point of Disease Progression — 2.0; 3.9; 2.0; 3.9 Percentage of participants

AstraZeneca Results Sep 2024 34.4% serious AE View details

Phase 2 N=23 A Study to Assess Biomarkers Impact on Participants Response to Erlotinib Treatment for First-line Non-Small Cell Lung Cancer With Endothelial Growth Factor Receptor (EGFR) Activating Mutations

Carcinoma，Non-Small-Cell Lung

Primary: Progression-Free Survival (PFS), as Assessed by Investigator Using Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST v1.1) — 387.000 days

Hoffmann-La Roche Results Apr 2017 21.7% serious AE View details

Phase 2 N=218 BIBW2992 (Afatinib) in Advanced (EGFR-FISH +) NSCLC (Non Small Cell Lung Cancer) Patients

Carcinoma, Non-Small-Cell Lung

Primary: Percentage of Participants With Best Objective Response — 13.0 percentage of participants

Boehringer Ingelheim Results Oct 2013 50.7% serious AE View details

Phase 4 N=60 Afatinib as Second-line Therapy for Lung Cancer With Epidermal Growth Factor Receptor (EGFR) Mutation

Carcinoma, Non-Small-Cell Lung

Primary: Objective Tumour Response (Complete Response [CR], Partial Response [PR]) as Assessed by the Investigator According to the RECIST Version 1.1 — 50 Percentage of…

Boehringer Ingelheim Results Dec 2018 35.0% serious AE View details

Phase 2 N=688 A Study to Assess the Incidence of EGFR Mutation in Patients With Newly Diagnosed Locally Advanced or Metastatic Non-Small Cell Lung Cancer in the UK, And of Tarceva (Erlotinib) as First-Line Therapy in EGFR Mutation Positive Patients.

Non-Squamous Non-Small Cell Lung Cancer

Primary: Percentage of Participants Who Tested Positive for EGFR Mutations — 8.1 percentage of participants

Hoffmann-La Roche Results Oct 2015 39.0% serious AE View details

Phase 2 N=109 BELIEF (Bevacizumab and ErLotinib In EGFR Mut+ NSCLC)

Lung Cancer

Primary: Progression Free Survival — 16; 10.5 months

ETOP IBCSG Partners Foundation Results Oct 2019 29.3% serious AE View details

Phase 4 N=107 Efficacy, Safety, Tolerability of Gefitinib as 1st Line in Caucasian Patients With EGFR Mutation Positive Advanced NSCLC

Caucasian Patients With EGFR Mutation Positive Advanced NSCLC

Primary: Objective Response Rate (ORR) (Investigator) — 69.8; 30.2 Percentage of Participants

AstraZeneca Results Oct 2013 19.6% serious AE View details

Phase 4 N=156 SELINE: Second-Line Iressa Phase IV Study in NSCLC Patients

Non Small Cell Lung Carcinoma

Primary: Objective Response Rate(ORR) — 31.2 Percent of participants

AstraZeneca Results Sep 2012 16.2% serious AE View details

Phase 2 N=123 Erlotinib Versus Pemetrexed as Second-Line Therapy in Treating Patients With Advanced Lung Adenocarcinoma

Lung Cancer

Primary: Progression-Free Survival — 4.1; 3.9 months

Si-Yu Wang Results Sep 2014 0.0% serious AE View details

Phase 3 N=14 Afatinib in Patients With Non Small Cell Lung Cancer (NSCLC) With Epidermal Growth Factor Receptor (EGFR) Mutations

Carcinoma, Non-Small-Cell Lung

Primary: Safety Assesment — 92.9; 35.7; 35.7; 21.4 Percentage of participants

Boehringer Ingelheim Results Mar 2017 21.4% serious AE View details

Phase 2 N=129 LUX Lung 2 Phase II Single Arm BIBW 2992 "Afatinib" in NSCLC With EGFR Activating Mutations

Carcinoma, Non-Small-Cell Lung

Primary: Objective Response (OR) as Determined by RECIST 1.0 — 62.0 percentage of participants

Boehringer Ingelheim Results Oct 2013 41.1% serious AE View details

Phase 3 N=542 Afatinib (BIBW 2992) in Advanced Non-Small Cell Lung Cancer Patients With EGFR Mutation

Carcinoma, Non-Small-Cell Lung

Primary: Percentage of Participants With Serious Adverse Events (SAEs) — 30.3 Percentage of participants (%)

Boehringer Ingelheim Results Aug 2019 30.3% serious AE View details

Phase 2 N=15 Osimertinib for NSCLC With EGFR Exon 20 Insertion Mutation

Locally Advanced or Metastatic NSCLC

Primary: Objective Response Rate — 0 Participants

Seoul National University Hospital Results Feb 2025 53.3% serious AE View details

Phase 3 N=168 S1403, Afatinib Dimaleate With or Without Cetuximab in Treating Patients With Newly Diagnosed Stage IV or Recurrent, EGFR Mutation Positive Non-small Cell Lung Cancer

Recurrent Non-Small Cell Lung Carcinoma · Stage IV Non-Small Cell Lung Cancer

Primary: 2-year Overall Survival Rate — 67; 70 percentage of participants — p=0.44

SWOG Cancer Research Network Results Mar 2021 36.2% serious AE View details

Phase 2 N=143 Erlotinib (Tarceva) as a Single Agent or Intercalated With Combination Chemotherapy in Patients With EGFR Positive NSCLC

Carcinoma, Non-Small-Cell Lung

Primary: 6-month Progression-free Survival — 30.7; 26.4 Percentage of Patients

OSI Pharmaceuticals Results Feb 2011 39.4% serious AE View details

Phase 2 N=17 A Study Osimertinib in Patients With Stage 4 Non-small Cell Lung Cancer With Uncommon EGFR Mutations

Non Small Cell Lung Cancer

Primary: Objective Response Rate as Assessed by the Investigator Using Response Evaluation Criteria In Solid Tumors (RECIST 1.1) — 8 Participants

Duke University Results Oct 2023 11.8% serious AE View details

N/A N=161 GIOTRIF in First Line Therapy of Advanced NSCLC With EGFR-mutations

Carcinoma, Non-Small-Cell Lung

Primary: Progression Free Survival (PFS) Rate After 12 Months — 50.24 Percent probability of PFS

Boehringer Ingelheim Results Jan 2020 42.8% serious AE View details

Phase 2 N=30 A Study of Erlotinib in Participants With Locally Advanced or Metastatic Non-Small Cell Lung Cancer With Epidermal Growth Factor Receptor Mutations

Non-Squamous Non-Small Cell Lung Cancer

Primary: Percentage of Participants With Objective Response (Complete Response [CR]/Partial Response [PR]) Based on Computer Tomography (CT) or Magnetic Resonance Imaging (MRI)…

Hoffmann-La Roche Results Oct 2018 26.7% serious AE View details

Phase 2 N=210 Phase II AZD9291 Open Label Study in NSCLC After Previous EGFR TKI Therapy in EGFR and T790M Mutation Positive Tumours

Non Small Cell Lung Cancer

Primary: Objective Response Rate (ORR) — 70.9 % of participants

AstraZeneca Results Jun 2016 20.0% serious AE View details

Phase 2 N=18 Afatinib in NSCLC With HER2 Mutation

Carcinoma, Non-Small-Cell Lung

Primary: Percentage of Patients With Objective Response (OR) in Part A According to Response Evaluation Criteria in Solid Tumours (RECIST) 1.1 — 0.0 Percentage of participants

Boehringer Ingelheim Results Oct 2019 33.3% serious AE View details

Phase 3 N=364 BIBW 2992 (Afatinib) vs Gemcitabine-cisplatin in 1st Line Non-small Cell Lung Cancer (NSCLC)

Carcinoma, Non-Small-Cell Lung · Adenocarcinoma

Primary: Progression-free Survival — 11.01; 5.59 months — p=<0.0001

Boehringer Ingelheim Results Jan 2015 14.8% serious AE View details

Phase 2 N=6 A Study of Tarceva (Erlotinib) in Patients With Locally Advanced, Metastatic or Recurrent Non-Small Cell Cancer Who Present Epidermal Growth Factor Receptor Mutations

Non-Squamous Non-Small Cell Lung Cancer

Primary: Progression-free Survival (Tumour Assessments According to RECIST Criteria) — 223 Days

Hoffmann-La Roche Results Nov 2015 16.7% serious AE View details

Phase 3 N=256 T790M Plasma Testing Methodology Comparison and Clinical Validation

Lung Cancer

Primary: Concordance — 91.3; 66.8; 82.7; 86.1 percentage of aggrement

AstraZeneca Results Mar 2024 View details

Phase 2 N=171 Phase II Single Arm Study of AZD9291 to Treat NSCLC Patients in Asia Pacific

Non-Small Cell Lung Cancer

Primary: ORR According to RECIST 1.1 by Independent Review — 62.0 % of participants

AstraZeneca Results Apr 2017 24.6% serious AE View details

Phase 2 N=23 A Study of Atezolizumab in Combination With Bevacizumab in Patients With EGFR Mutation Positive Stage IIIB-IV Non-Squamous Non-Small Cell Lung Cancer

Carcinoma, Non-Small-Cell Lung

Primary: Objective Response Rate (ORR) — 18.2 Percentage of Participants

Hoffmann-La Roche Results Apr 2023 17.4% serious AE View details

Clinical Trial Search

N/A N=314 T790M Mutation on ctDNA in Patients With NSCLC After EGFR-TKI Failure

Phase 2 N=100 Erlotinib in Patients With Resected, Early Stage NSCLC With Confirmed Mutations in the EGFR

N/A N=462 The Study Observes How Long Patients With Non-small Cell Lung Cancer (NSCLC) Benefit From Treatment With Epidermal Growth Factor Tyrosine Kinase Inhibitor (EGFR-TKI) When Given Either for Uncommon Mutations or for Common Mutations in the Sequence Afatinib Followed by Osimertinib

N/A N=3,382 Asia Pacific and Russia Diagnostic Study for EGFR Testing

Phase 2 N=41 Single-arm Trial of BIBW 2992 (Afatinib) in Demographically and Genotypically Selected NSCLC Patients

Phase 2 N=154 A Molecular Profiling Study of Patients With EGFR Mutation-positive Locally Advanced or Metastatic NSCLC Treated With Osimertinib

Phase 2 N=23 A Study to Assess Biomarkers Impact on Participants Response to Erlotinib Treatment for First-line Non-Small Cell Lung Cancer With Endothelial Growth Factor Receptor (EGFR) Activating Mutations

Phase 2 N=218 BIBW2992 (Afatinib) in Advanced (EGFR-FISH +) NSCLC (Non Small Cell Lung Cancer) Patients

Phase 4 N=60 Afatinib as Second-line Therapy for Lung Cancer With Epidermal Growth Factor Receptor (EGFR) Mutation

Phase 2 N=688 A Study to Assess the Incidence of EGFR Mutation in Patients With Newly Diagnosed Locally Advanced or Metastatic Non-Small Cell Lung Cancer in the UK, And of Tarceva (Erlotinib) as First-Line Therapy in EGFR Mutation Positive Patients.

Phase 2 N=109 BELIEF (Bevacizumab and ErLotinib In EGFR Mut+ NSCLC)

Phase 4 N=107 Efficacy, Safety, Tolerability of Gefitinib as 1st Line in Caucasian Patients With EGFR Mutation Positive Advanced NSCLC

Phase 4 N=156 SELINE: Second-Line Iressa Phase IV Study in NSCLC Patients

Phase 2 N=123 Erlotinib Versus Pemetrexed as Second-Line Therapy in Treating Patients With Advanced Lung Adenocarcinoma

Phase 3 N=14 Afatinib in Patients With Non Small Cell Lung Cancer (NSCLC) With Epidermal Growth Factor Receptor (EGFR) Mutations

Phase 2 N=129 LUX Lung 2 Phase II Single Arm BIBW 2992 "Afatinib" in NSCLC With EGFR Activating Mutations

Phase 3 N=542 Afatinib (BIBW 2992) in Advanced Non-Small Cell Lung Cancer Patients With EGFR Mutation

Phase 2 N=15 Osimertinib for NSCLC With EGFR Exon 20 Insertion Mutation

Phase 3 N=168 S1403, Afatinib Dimaleate With or Without Cetuximab in Treating Patients With Newly Diagnosed Stage IV or Recurrent, EGFR Mutation Positive Non-small Cell Lung Cancer

Phase 2 N=143 Erlotinib (Tarceva) as a Single Agent or Intercalated With Combination Chemotherapy in Patients With EGFR Positive NSCLC

Phase 2 N=17 A Study Osimertinib in Patients With Stage 4 Non-small Cell Lung Cancer With Uncommon EGFR Mutations

N/A N=161 GIOTRIF in First Line Therapy of Advanced NSCLC With EGFR-mutations

Phase 2 N=30 A Study of Erlotinib in Participants With Locally Advanced or Metastatic Non-Small Cell Lung Cancer With Epidermal Growth Factor Receptor Mutations

Phase 2 N=210 Phase II AZD9291 Open Label Study in NSCLC After Previous EGFR TKI Therapy in EGFR and T790M Mutation Positive Tumours

Phase 2 N=18 Afatinib in NSCLC With HER2 Mutation

Phase 3 N=364 BIBW 2992 (Afatinib) vs Gemcitabine-cisplatin in 1st Line Non-small Cell Lung Cancer (NSCLC)

Phase 2 N=6 A Study of Tarceva (Erlotinib) in Patients With Locally Advanced, Metastatic or Recurrent Non-Small Cell Cancer Who Present Epidermal Growth Factor Receptor Mutations

Phase 3 N=256 T790M Plasma Testing Methodology Comparison and Clinical Validation

Phase 2 N=171 Phase II Single Arm Study of AZD9291 to Treat NSCLC Patients in Asia Pacific

Phase 2 N=23 A Study of Atezolizumab in Combination With Bevacizumab in Patients With EGFR Mutation Positive Stage IIIB-IV Non-Squamous Non-Small Cell Lung Cancer